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Abstract
Background: Bleeding is a frequent complication during surgery. The intraoperative
administration of blood products, including packed red blood cells, platelets and fresh frozen
plasma (FFP), is often live saving. Complications of blood transfusions contribute considerably to
perioperative costs and blood product resources are limited. Consequently, strategies to optimize
the decision to transfuse are needed.
Bleeding during surgery is a dynamic process and may result in major blood loss and coagulopathy
due to dilution and consumption. The indication for transfusion should be based on reliable
coagulation studies. While hemoglobin levels and platelet counts are available within 15 minutes,
standard coagulation studies require one hour. Therefore, the decision to administer FFP has to be
made in the absence of any data. Point of care testing of prothrombin time ensures that one major
parameter of coagulation is available in the operation theatre within minutes. It is fast, easy to
perform, inexpensive and may enable physicians to rationally determine the need for FFP.
Methods/Design: The objective of the POC-OP trial is to determine the effectiveness of point of
care prothrombin time testing to reduce the administration of FFP. It is a patient and assessor blind,
single center randomized controlled parallel group trial in 220 patients aged between 18 and 90
years undergoing major surgery (any type, except cardiac surgery and liver transplantation) with an
estimated blood loss during surgery exceeding 20% of the calculated total blood volume or a
requirement of FFP according to the judgment of the physicians in charge. Patients are randomized
to usual care plus point of care prothrombin time testing or usual care alone without point of care
testing. The primary outcome is the relative risk to receive any FFP perioperatively. The inclusion
of 110 patients per group will yield more than 80% power to detect a clinically relevant relative risk
of 0.60 to receive FFP of the experimental as compared with the control group.
Published: 23 November 2009
Trials 2009, 10:107 doi:10.1186/1745-6215-10-107
Received: 15 September 2009
Accepted: 23 November 2009
This article is available from: http://www.trialsjournal.com/content/10/1/107
© 2009 Urwyler et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
Trials 2009, 10:107 http://www.trialsjournal.com/content/10/1/107Discussion: Point of care prothrombin time testing in the operation theatre may reduce the
administration of FFP considerably, which in turn may decrease costs and complications usually
associated with the administration of blood products.
Trial registration: NCT00656396
Background
In patients undergoing major non-cardiac surgery there is
no established way of monitoring coagulation in real
time. In case of intraoperative bleeding, decisions to trans-
fuse fresh frozen plasma (FFP) and procoagulatory drugs
have to be taken clinically. Bleeding is a frequent compli-
cation during major surgery and can necessitate the trans-
fusion of blood products and/or procoagulatory drugs [1].
Complications of blood transfusions contribute consider-
ably to patient morbidity [2-10] and perioperative costs
[11-13]. In patients undergoing major non-cardiac sur-
gery there is no established way of monitoring coagula-
tion during surgery. In case of intraoperative bleeding,
decisions to transfuse fresh frozen plasma and procoagu-
latory drugs are based on clinical judgment only. In view
of the risk associated with administration of blood prod-
ucts, the unsatisfactory decision making process and the
scarcity of blood products, strategies to optimize intraop-
erative decision making are much needed.
A patient's bleeding risk may be anticipated based on the
patient's diagnosis or on the underlying surgical problem
[14-16]. However, the extent of bleeding is not predicta-
ble before surgery. Intraoperative bleeding is a dynamic
process and major blood loss can occur within minutes
with potentially life threatening consequences. Major
bleeding can lead to coagulation aberration due to dilu-
tion and consumption of coagulation factors [17]. While
hemoglobin levels and platelet counts are readily availa-
ble within 15 minutes, standard coagulation tests have
long turn around times of 45 minutes to one hour [18].
Moreover, analyses of specific coagulation factors take up
to six hours and results may only be available the next
day. These analyses are not performed with emergency
priority, some are not even available during night. An
intraoperative control of laboratory values is always con-
sidered as emergency analysis. Due to the inexistence of
intraoperative real time results of standard coagulation
studies, the decision to transfuse fresh frozen plasma and
procoagulatory drugs during non-cardiac surgery is based
on clinical judgment in practice, depending on the experi-
ence and/or the subjective decisions of the attending phy-
sicians [19].
Point-of-Care (PoC) devices are considerably faster than
the standard laboratory methods [20,21]. Several point-
of-care tests for standard coagulation parameters and two
different systems for thromboelastography are currently
marketed. None of the PoC tests, however, is approved for
intraoperative real time measurement of coagulation. One
potential intra-operative bedside coagulation study sys-
tem is thromboelastography [22]. It is a viscoelastic test of
whole blood clotting, which provides information about
the initiation of coagulation, about clot firmness and clot
lyses. It is costly and needs trained personnel with a work-
load of about 15 minutes to get first results. Its use is sug-
gested for cardiac surgery and liver transplantation
[23,24]. During major surgery the use of thromboelastog-
raphy is limited by costs, workload, the need for trained
personnel, analysis time, and difficulties in interpreting
results.
The use of a coagulation test based transfusion algorithm
leads to a reduction in the use of blood products [25,26].
There is no validated, standardized method for measuring
intraoperative blood loss. Blood loss during an operation
is difficult to quantify [27] and its underestimation might
be frequent. Coagulopathic bleeding has to be distin-
guished from surgical bleeding [28]. Therefore coagula-
tion parameters must be measured intraoperatively when
major bleeding occurs and decisions for or against the
transfusion of blood products and procoagulatory drugs
have to be made [1]. The availability of coagulation tests
is crucial for any algorithm used for decision making on
intra-operative substitution of blood products.
PoC devices could be used in the intraoperative setting to
guide the use of the costly blood bank resources and/or
procoagulatory drugs. In this study we will use a transfu-
sion algorithm based on the ASA Guidelines [1,12] and
point of care measurement of prothrombin time.
Methods/Design
Objective
To determine the effectiveness of an intraoperative deci-
sion algorithm based on PoC testing of prothrombin time
in reducing the administration of fresh frozen plasma.
Study design
The POC-OP trial is an ongoing, patient and assessor
blind, parallel-group, single-center randomized control-
led trial. Patients are randomized to (1) current clinical
treatment and perioperative care plus point of care pro-
thrombin time testing or (2) current clinical treatmentPage 2 of 9
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evaluating a combination of test strategies and subse-
quent treatments require a pre-specified link between test
results and management decisions [29]. In the POC-OP
trial, the treatment options and their relation with the dif-
ferent PoC test results are specified in the algorithm (fig-
ure 1 and figure 2).
Patient population
Men and women of at least 18 years of age undergoing
major surgery (orthopedic surgery, trauma surgery, neuro-
surgery, plastic and reconstructive surgery, ear-nose-throat
surgery, urologic surgery, gynecologic surgery, thoracic
surgery, visceral surgery) are eligible if their preoperative
estimated blood loss during surgery exceeds 20% of the
individually calculated normal total blood volume or if
the treating anesthesiologist or surgeon intends to give
fresh frozen plasma. Surgical management of platelet
aggregation inhibitors changed in 2007 for patients with
cardiac diseases and/or coronary artery stents [30]. There-
fore, we will consider all patients scheduled for operation,
even if anticoagulants or anti-platelet drugs were adminis-
tered.
Patients are not eligible if they have a history of hereditary
coagulopathies; are pregnant; have abnormal coagulation
studies before surgery (based on normal values for pro-
thrombin time: 70 - 130% and platelets: 140 - 380 G/l);
undergo liver transplantation; or patients receiving a
bolus of heparin intraoperatively (extracorporal circula-
tion 400 - 500 IU heparin per kg bodyweight, vascular sur-
gery 100 IU before clamping the artery). Prothrombin
time in patients under unfractionated heparin > 1 IU per
ml blood can impair the accuracy of the result of our PoC
Algorithm for the transfusion of fresh frozen plasmaFi u e 1
Algorithm for the transfusion of fresh frozen plasma. FFP = Fresh Frozen Plasma, PT = Prothrombin Time, Tc = 
Thrombocyts, PACU = Post Anesthesia Care Unit, aPTT = activated Partial Tromboplstine Time, TT = Thrombin Time.Page 3 of 9
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plex problem for coagulation than dilution or consump-
tion coagulopathy only [32]. During liver transplantation,
coagulation should be monitored by rotation thrombelas-
tometry [23]. PoC prothrombin time monitoring might
be helpful but not sufficient for complex coagulation
aberrations. Anesthetic management (general-, regional
or a combined anesthesia) is defined by the attending
anesthesiologist. Prothrombin time is not influenced by
anesthetic gases, propofol, opiates, muscle relaxants and
local anesthetics [33,34]. Propofol, desflurane, sevoflu-
rane or isoflurane are used for general anesthesia in our
Department. Regional Anesthesia is only performed in
patients with normal preoperative coagulation studies.
Allocation of patients
Informed consent of eligible patients is obtained on the
day before surgery. Patients with written informed con-
sent are randomly allocated to the experimental and con-
trol intervention only if their intra-operatively estimated
blood loss exceeds 20% of the patients calculated normal
total blood volume (70 ml per kg body weight) or if their
treating anesthesiologist or surgeon intends to give fresh
frozen plasma (Figure 3).
Allocation is done in a 1:1 fashion based on a computer-
generated random list, with randomly varying blocks of
four and six. Sealed, opaque, sequentially numbered,
tamper-proof security envelopes are used to conceal allo-
cation. Preparation of envelopes was done by personnel
independent of patient recruitment.
Perioperative care
An attending anesthesiologist is in charge of all decisions
regarding anesthesia and transfusion of blood products.
Residents in anesthesiology work continuously under
Algorithm for the transfusion of plateletsFi u e 2
Algorithm for the transfusion of platelets. FFP = Fresh Frozen Plasma, PT = Prothrombin Time, Tc = Thrombocyts, 
PACU = Post Anesthesia Care Unit.Page 4 of 9
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Study flow for individual patientsFigure 3
Study flow for individual patients.
Trials 2009, 10:107 http://www.trialsjournal.com/content/10/1/107supervision of the attending physician. During the trial,
the attending anesthesiologist ensures that the trial proto-
col is followed properly.
When the intraoperative estimated blood loss exceeds
20% of the individuals total blood volume, or if their
treating anesthesiologist or surgeon intends to give fresh
frozen plasma, patients are randomized as described
above and patient management determined according to
the group assignment.
All patients receive allogenic blood products according to
pre-defined transfusion algorithms (Figure 1 and Figure
2). Both algorithms were developed based on a literature
review [1,12,13] and recommendations by in-house
hematologists.
The landmarks of the algorithms are:
- Blood loss of more than 20%
- Clinical assessment of bleeding type, i.e. massive or not
by the attending physicians
- Prothrombin time of less than 50%
- Platelet count of less than 50.000 per liter
Blood samples for all coagulation studies are drawn from
arterial and central venous lines, peripheral venous lines,
by direct venipuncture or capillary, according to the stand-
ard operating procedure of the University Department of
Anesthesiology and Pain Therapy of the University Hospi-
tal Bern. Prothrombin time is measured according to the
randomization and transfusion of fresh frozen plasma
based on available results of the prothrombin time test
and clinical judgment (Figure 1). For both groups, platelet
counts are done in the central hematology laboratory of
the University Hospital Bern and thrombocytopenia is
treated according to the algorithm (Figure 2). Hemo-
globin is measured PoC in the operating room by
Hemocue (B-Hemoglobinphotometer Hemocue® AB,
Ängelholm, Sweden) and/or in the central hematology
laboratory. In case of anemia, erythrocytes are transfused
according to the standard operating procedure of the
Department of Anesthesiology based on ASA guidelines
(1). Platelet counts and hemoglobin levels as measured by
the central hematology laboratory are usually available
within 15 minutes. The central hematology laboratory has
an ISO/IEC 17025 accreditation [35].
Postoperative care is the same for both groups. Pain treat-
ment consists of continuous regional anesthesia, opioids
either continuous or per bolus, as well as paracetamol,
metamizol and NSAIDs.
Experimental intervention
According to the transfusion algorithm (Figure 1) bedside
prothrombin time (PT) is measured by a PoC device
(CoaguChek XS Plus® Roche Diagnostics, Basel, Switzer-
land) and immediately available for decision-making. We
have demonstrated the high diagnostic accuracy of Coag-
uChek in a previous study. [36] Of note, agreement for
prothrombin time values between capillary and venous or
arterial blood was evaluated and showed good agreement
[37].
Control intervention (standard care)
Patients in the control group are transfused according to
the same algorithms and triggers as in the experimental
group. However, in the absence of the PoC device, pro-
thrombin time is measured in the central hematology lab-
oratory by BCS coagulation systems (BCS, Siemens
Healthcare Diagnostics, USA). Considering a turn around
time which usually exceeds 40 minutes [18], the results of
intra-operative prothrombin time measurements in the
control group are usually not available for decision-mak-
ing. Decisions for a transfusion of fresh frozen plasma in
the standard care group are therefore based on clinical
judgment only.
Emergencies
In case of life threatening rapid massive blood loss with
no time to take blood samples for coagulation studies, the
anesthesiologist is allowed to deviate from the protocol at
his or her discretion.
Assessments
The following assessments are performed for all rand-
omized patients regardless of any protocol deviations:
Preoperative
Patient's demographics, American Society of Anesthesiol-
ogy physical health status classification, coagulation his-
tory, surgical diagnosis, other secondary diagnosis, drugs
with influence on coagulation or platelet function (cou-
marine-derivatives, platelet aggregation inhibitors,
unfractionated heparin, low molecular weight heparins,
non-steroidal anti-inflammatory drugs), time when these
drugs were stopped, other long-term medication, surgical
discipline, planed operation, planed anesthesia, preoper-
ative hemoglobin level, prothrombin time and platelet
count.
Post-operative
Type and duration of operation; type and duration of
anesthesia; intraoperative blood loss, transfused blood
products, amount and type of i.v. fluids, procoagulatory
drugs and amount, laboratory studies, serious intra-oper-
ative adverse events, life threatening bleeding resulting in
life-saving measures and consecutive protocol violations.Page 6 of 9
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Transfused blood products since end of surgery, amount
and type of i.v. fluids, procoagulatory drugs, laboratory
values at the end of surgery and 24-h later: laboratory
studies. Duration of stay in post-anesthesia care unit in
hours, duration of stay in ICU in hours, reoperation due
to bleeding, serious adverse events, survival.
Hospital discharge or 7st day post operation
Transfused blood products, procoagulatory drugs, dura-
tion of stay in post anesthesia care unit in hours, duration
of stay in intensive care unit in hours, duration of hospi-
talization since randomization, reoperation due to bleed-
ing, serious adverse events, vital status.
Follow-up at 6 months
Re-hospitalization and days of hospitalization, reopera-
tion due to bleeding, serious adverse events, vital status.
Outcomes
The primary outcome of the trial is:
1) the relative risk of receiving any fresh frozen plasma
in-hospital, defined as the administration of at least
0.5 units of fresh frozen plasma received after rand-
omization until day 7 after surgery or post-operative
discharge from hospital, whatever comes first.
Secondary outcomes are:
2) the number of units of fresh frozen plasma received
after randomization until day 7 or post-operative dis-
charge from hospital, whatever comes first;
3) the number of units of allogenic blood products
transfused
4) the relative risk of major in-hospital bleeding
defined as bleeding event requiring an extension of
hospitalization, reoperation due to bleeding, bleeding
resulting in hemorrhagic shock or death after rand-
omization until day 7 or post-operative discharge
from hospital, whatever comes first;
5) the relative risk of a serious adverse event (non-fatal
myocardial infarction, non-fatal stroke, cardiovascular
death, or death of unknown cause) [38] received after
randomization until day 7 or post-operative discharge
from hospital, whatever comes first;
6) the relative risk of overall mortality received after
randomization until day 7 or post-operative discharge
from hospital, whatever comes first.
Other exploratory outcomes of interest are: the estimated
extent of blood loss, the relative risk of a serious adverse
events; the relative risk of a reoperation because of a
bleeding complication; the relative risk of receiving any
allogenic blood product; the relative risk of a systemic
inflammatory response syndrome (SIRS) or sepsis; the rel-
ative risk of an infection of the surgical wound; the com-
pliance with the allocated intervention.
In-hospital outcomes are ascertained by study personnel
unrelated to the care of randomized patients and 6-month
data is recorded by telephone interviewers. Patients, study
personnel recording outcome data in-hospital and tele-
phone interviewers ascertaining 6-month data are blind as
to the allocated intervention.
Sample size
The POC-OP trial is a superiority trial. A review of 40 ran-
domly selected patients in our institution with major
orthopedic surgery and an intraoperative blood loss of at
least 20% revealed that 50% of these patents received
fresh frozen plasma. Consequently, a baseline risk of 50%
of receiving fresh frozen plasma was assumed for the sam-
ple size calculation. We defined a relative risk of 0.60 of
receiving fresh frozen plasma as minimally clinically rele-
vant relative risk. A sample size of 110 patients per study
arm will provide more than 80% power to detect a relative
risk of 0.60 at a two-sided alpha level of 5%.
Statistical analysis
The trial statistician will be blinded to the allocated inter-
vention for all analyses.
All analyses will be based on the intention-to-treat princi-
ple, whereby all randomized patients will be included in
the analysis in the group they were allocated regardless of
the intervention received.
Binary data will be analyzed using the chi-squared test.
Continuous data will be analyzed using Student's t-test.
Missing values will be imputed using multiple imputation
[39]. For stratified analyses of the primary outcome we
will use formal tests of interaction between allocated
interventions and subgroup in multivariable logistic
regression models [40]. The following stratification fac-
tors will be analyzed: PT ≥ 90% versus PT < 90% at base-
line; trauma/emergency versus elective surgery;
orthopedic versus other surgeries; American Society of
Anesthesiology physical health status classification ≥ 4
versus American Society of Anesthesiology physical health
status classification < 4.
Ethical approval
The POC-OP randomized-controlled trial has been
approved by the ethic committee of the canton of Bern
(41), ref. nr.: 232/06Page 7 of 9
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Source data verification of selected data is performed by
an independent monitor of CTU Bern in a random sample
of 40 patients. The following data is monitored: eligibility
criteria, hemoglobin at baseline, American Society of
Anesthesiology physical health status classification status,
compliance with allocated intervention. In case of dis-
crepancies in more than 14 per 1000 data points, we will
perform a source-data verification in all patients. Written
informed consent is verified by the monitor in all patients.
Discussion
The transfusion of blood products can be live saving, but
carries substantial side effects for the patient [2-10]. There-
fore, the indication for the administration of allogenic
blood products has to be weighed up against the risks for
the patient. Also, blood products are a scarce resource
necessitating their efficient use. Until today there is no sat-
isfying option to monitor the dynamic process of intraop-
erative bleeding without considerable delay and high
costs.
The study project is designed to evaluate a simple method,
which ensures that results of coagulation studies become
available to the anesthesiologist in charge without delay.
To reflect modern concepts of decision making, we cre-
ated a transfusion algorithm, which follows ASA guide-
lines [1,12]. PoC testing in the operation theatre in
combination with this algorithm may reduce the admin-
istration of fresh frozen plasma considerably, which in
turn may decrease costs and complications usually associ-
ated with the administration of allogenic blood products.
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